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Skin disease research involving children
currently faces several major hurdles.
As a result, many therapies are only
available for off-label use in children,
and many of the most pressing clinical
needs of our pediatric population
remain unsolved. A strategic planning
committee of the Society for Pediatric
Dermatology (SPD) identified the need
for an organized, inclusive research
alliance to augment the resources of
individual practitioners and preexisting
smaller collaborative groups and
facilitate robust, multicenter-based,
translational and clinical research and
therapeutic trials. A December 2011
National Institute of Arthritis and Mus-
culoskeletal and Skin Diseases (NIAMS)
Roundtable on Pediatric Dermatology
further detailed the therapeutic gaps
and barriers to translation of scientific
advances to clinical practice. Building
on these forums, in July 2012, a group of
interested investigators met in Monterey,
CA, to develop the infrastructure for
collaborative pediatric skin research,
now called the Pediatric Dermatology
Research Alliance (PeDRA). The
vision of PeDRA is to create sustainable
collaborative research networks to
better understand, prevent, treat, and
cure dermatologic diseases in children.
From that starting point, subcommittees
and expert members were added, stake-
holders were identified, and seed funding
was garnered, with the first PeDRA stand-
alone research meeting realized in Chi-
cago, IL, in October 2013.
The inaugural PeDRA meeting
The goals of this inaugural meeting were
to generate a new forum for interactions
between clinicians and basic scientists
and to foster collaborative research pro-
jects in pediatric dermatology. This
meeting was also intended to inspire
and train the next generation of clinical
investigators, provide an infrastructure
for regular interchange for existing and
future PeDRA working groups, and
create a venue for interaction with
advocacy organizations. This 2½-day
conference with 75 attendees featured
educational seminars including a key-
note address, didactic lecture sessions,
reports from disease advocacy groups,
a poster session, and an interactive
evening session in which abstracts of
research proposals were discussed. Four
moderated disease-specific work groups
met to develop strategies for design and
implementation of collaborative studies,
and later presented reports stating their
goals for the next year. Relationships
were cultivated through a speed net-
working exercise in which the partici-
pants shared their ongoing research
projects and future goals. A PeDRA
business meeting was conducted on
the final day.
Topics covered in didactic sessions
Lessons on collaborative research
Peter Adamson, Children’s Hospital of
Philadelphia (CHOP), Chair of the
Children’s Oncology Group (COG), pre-
sented an overview of the formation of
this 50þ -year collaborative network of
investigators devoted to curing pediatric
cancer. COG, like PeDRA, arose from
the shared recognition of the need for
multicenter collaboration to advance
the field. A key to COG’s success has
been the strong culture of research
embedded within the specialty, such
that greater than 90 percent of US
children diagnosed with cancer partici-
pate in clinical trials. These efforts have
substantially increased survival rates for
multiple childhood cancers. Member-
ship in COG is transdisciplinary, and
includes hematologist-oncologists, sur-
geons, radiation oncologists, pharma-
cists, laboratory scientists, epidemio-
logists, and others. He discussed the
value of partnerships with industry, via
the provision of scientific expertise,
access to patient populations, single
contract negotiation for many study
sites, and a high volume of subjects,
and stressed the need for engagement of
junior investigators, early involvement
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of COG investigators in the design of
industry-sponsored studies, and the
facilitation of communication among
member sites using web-based centra-
lized data systems.
Keys for success in clinical research
David Cella, director of the Northwes-
tern University Center for Patient-Cen-
tered Outcomes, shared his experiences
with multiple collaboratives, including
those studying cancer, obesity, and out-
come measurements. With the current
focus on making informed health deci-
sions based on the quality and relevance
of evidence, patient-centered outcomes
research (PCOR) and comparative effec-
tiveness research (CER) opportunities
have multiplied. Mechanisms for mea-
suring such outcomes include the
Patient Reported Outcomes Measure-
ment Information System (PROMIS,
www.nihpromis.org) and PROsetta
Stone (www.prosettastone.org). Com-
parative effectiveness research can be
administrative, patient-reported, and/or
clinical, and is best performed with
integration and utilization of Electronic
Health Records for data collection.
Building patient registries
Mary Schwartz, Director of the Pachyo-
nychia Congenita (PC) Project, spoke
about registry development issues, using
the International PC Research Registry
(IPCRR) as an example. Key questions in
building a patient registry include decid-
ing what data to gather, how to gather it,
data ownership and sharing, and deter-
mining what is gained from data.
Patients, researchers, and clinicians
should be involved in the registry
design, and data collection methods
should reflect the environment of each
accessible population. Advances in
technology have facilitated exponential
growth of IPCRR from 3 patients in one
state in 2004 to 1,309 patients in 65
countries in 2013. For IPCRR, patients
ultimately own the data, and project
leaders serve as custodians of the data
and as patient advocates. The IPCRR
can now provide genetic testing for
every patient; gene mutation results
led to PC reclassification into five sub-
types. Registry data have generated
improved care and community support,
along with collaborative publications,
research studies, and clinical trials.
which ideally will lead to effective
treatments and eventually a cure.
Patient recruitment and retention
Lawrence Eichenfield, University of
California, San Diego (UCSD), discussed
the types of study designs that might be
employed in PeDRA studies, including
epidemiological, tissue-based, and inter-
ventional studies. He stressed the impor-
tance of The Belmont Report in the
ethical protection of human subjects of
research. When working with children,
study design and focus on value are
critical. Recruitment strategies include
using institutional and IRB-approved
postings, as well as conventional and
social media. Offering evening or week-
end hours for study visits can improve
patient retention and satisfaction. Finally,
he highlighted that excellent communi-
cation with patients, referring providers,
and advocacy groups is essential.
Pitfalls for the multicenter IRB
Dennis West, Northwestern University,
presented the top pitfalls related to
multicenter IRBs. He advised that each
site must maintain good relationships
with local and central IRBs and each
may be subject to audits. A site using a
central IRB may not be exempt from the
need for local IRB approval. Similarly, at
the end of a study, sites using a central
IRB must individually close their study
with their local IRBs. Requirements for
consent forms, data usage agreements,
and data coordinating centers were
reviewed. Posting clinical trials and
studies on Clinicaltrials.gov is important
for transparency and later publication.
Getting the most out of your institutional
resources
Donald Lloyd-Jones, Director of the
Northwestern University Clinical and
Translational Sciences Institute, high-
lighted web- and technology-based
tools available to facilitate collaborative
research. He demonstrated VIVO, a
system to link researchers with synergis-
tic research goals or skills. Involving
biostatisticians and bioinformatics
experts and using database software
programs like REDCap are keys to suc-
cess in clinical and translational
research. Institutional resources, such
as technology transfer and clinical trials
offices, can provide training programs,
career development awards, and NIH
grant-writing seminars for clinician-
scientists. A variety of funding sources
should be considered, including NIH
and institutional grants, philanthropy,
and seed funds. He also stressed the
importance of community engagement
and input from stakeholders.
Update: BPCA dermatology therapeutics
area working group
Elaine Siegfried, Saint Louis University,
noted that the Best Pharmaceuticals for
Children Act (BPCA) provides incentives
for pediatric studies, with the ultimate
goal of establishing pediatric labeling
for safe/effective drug use. In 2012, der-
matology was recognized as an impor-
tant area of unmet need. With the input
of more than 30 pediatric dermatologists
and presentation to the FDA and BPCA,
four areas of therapeutic need were
identified: atopic dermatitis, heman-
gioma of infancy, epidermolysis bullosa
and other genodermatoses, and pedia-
tric dermatology drug development.
Scientific program: chaired by Keith
Choate, Yale
Shrikant Mane, Director of the Yale
Center for Genome Analysis, introduced
the Centers for Mendelian Genetics, for
which Yale is one site. He described
Yale’s advances in sequencing technol-
ogy and the application of exome seq-
uencing to identification of genes causing
cardiovascular, kidney, and neurologic
disorders. Keith Choate detailed use of
next-generation sequencing approaches
to study rare, inherited, and mosaic skin
disorders, highlighting the efforts of
PeDRA collaborations in determining
the genetic basis of the Cutaneous-
Skeletal Hypophosphatemia Syndrome
and Ichthyosis with confetti and
in encouraging additional collaborative
referrals.
Peter Elias, University of California,
San Francisco (UCSF), presented patho-
genesis-based approaches for disorders
of cornification and encouraged consid-
eration of pathogenesis-based therapies
for atopic dermatitis and psoriasis. These
therapies should be cost-effective and
disease-specific, with favorable safety
profiles.
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Breakout sessions
The Inflammatory Skin Disease
Collaborative, moderated by Wynnis
Tom, UCSD, and Kelly Cordoro, UCSF
Benefits of PeDRA collaborations can
include adequate powering of investiga-
tor-initiated and industry-sponsored stu-
dies through large numbers of sites
and their rapid mobilization, as well as
access to an expanded network of con-
tacts, including outside of pediatric der-
matology. These collaborative efforts
encompass multiple disorders, some
with a history of multicenter collabora-
tion and others needing development.
Six focus areas were defined: psoriasis;
atopic dermatitis; acne and hidradenitis;
connective tissue and autoinflammatory
disorders; hair, nail, and special sites;
and therapeutics. Therapeutics, quality
of life measures, and patient-centered
outcomes research overlay multiple
areas. Initial pilot project ideas and
research needs were identified for each
focus area. Surveys and multicenter
studies that compare the efficacy and
adverse effects of systemic therapies for
atopic dermatitis and psoriasis are
among planned projects. In addition,
patient registries for multiple conditions,
including morphea, alopecia areata,
and preadolescent acne, are important
to facilitate research and determine
outcomes.
Birthmarks, moderated by Ilona Frieden,
UCSF, Beth Drolet, Medical College of
Wisconsin (MCW), and Albert Yan,
CHOP
The Birthmarks group focused on vas-
cular and pigmentary disorders. A study
of topical timolol usage for infantile
hemangiomas, with focus on pharma-
cokinetics and systemic absorption, was
discussed. High-risk groups for topical
timolol are of particular interest, includ-
ing premature infants, and juxtamuco-
sal, ulcerated, and genital sites. Group
challenges discussed included getting
multi-institutional IRB approval for stu-
dies involving tissue biopsies, and bank-
ing and exchanging patient materials
among institutions. The following could
be topics for potential study: genetics
and phenotypic characterization of
vascular overgrowth syndromes; a
retrospective study of pre-propranolol
ECGs for infants with hemangiomas; a
retrospective study of patients receiving
sirolimus for vascular anomalies; and
retrospective and prospective studies of
propranolol usage in preterm infants.
Epidermolysis Bullosa (EB) and Other
Genetic Disorders, moderated by Anna
Bruckner, University of Colorado Health
Science Center, and Joyce Teng, Stanford
University
The existing Epidermolysis Bullosa Clin-
ical Research Consortium (EBCRC)
includes 16 centers in the USA and
Canada, 14 of which have IRB approval
for the EB Clinical Characterization and
Outcomes Database (CCOD), the main
project of EBCRC. The CCOD database
is used to evaluate the prevalence,
severity, and health risks of anemia in
EB patients and is a source for identify-
ing patients for participation in future
clinical trials. Other ongoing EBCRC
projects are investigating the impact of
bacterial colonization in wound healing
and the significance of antimicrobial
resistance in EB care. The iscorEB
outcome measure is now available
as a mobile app. Obtaining genetic tests
for definitive diagnosis has been
challenging, with B50% of pediatric
dermatologists reporting difficulty in
obtaining approval, a major focus for
future advocacy.
A longitudinal study of the natural
history of Basal Cell Carcinoma Nevus
Syndrome (BCCNS) from childhood to
adult years, with creation of a disease
registry, was also discussed. Other
BCCNS projects include the following:
development of a treatment algorithm
for skin lesions and systemic manifesta-
tions during childhood; assessing pedia-
tric indications for new treatments (eg,
hedgehog inhibitors) that are not cur-
rently FDA-approved for pediatric use
(e.g., odontogenic jaw cysts); and safety
monitoring for medication use. Devel-
oping EMR content specific to pediatric
dermatology using existing data sets will
help in evaluating the cost-effectiveness
for these rare genetic disorders.
Disorders of Cornification, moderated by
Mary Williams, UCSF, and Keith Choate
The Disorders of Cornification (DOC)
Working Group has individuals with
over four decades of experience in the
care and research of these disorders.The
Foundation for Ichthyosis and Related
Skin Types (FIRST), the primary patient
advocacy group for DOC, has facilitated
clinical and basic research and engaged
many PeDRA members. The Pachyony-
chia Congenita Project (PC Project) was
also represented, and discussion cen-
tered on the need for longitudinal data
on outcomes and complications for
ichthyoses. All participants in longitudi-
nal studies should be genotyped, either
commercially or through a research
study, as clinical diagnosis can be diffi-
cult, especially in the newborn period.
Evidence-based guidelines for care of
the neonate with ichthyosis need to be
developed, based on improved under-
standing of potential complications and
the risks and benefits of interventions. A
cooperative longitudinal, observational
study of childhood through adult years
should be undertaken to define the
natural history of disease, as well as
prognosis and complications in relation
to genotype, and to better understand
the growth and development and audi-
tory or ocular issues. The need to
ascertain biomarkers for evaluating
potential therapeutic agents was dis-
cussed. Development of a centralized
system for data entry will require fund-
ing. Another focus area was skin care of
the neonate, with particular emphasis
on the problems of prematurity. An
international effort to survey skin care
practices in neonatal nurseries and
develop guidelines is ongoing. The
group identified the need to connect
with neonatologists and neonatal nur-
sing groups.
Advocacy group presentations
Patient advocacy organizations were
invited to participate, and six attended:
The BCCNS Life Support Network,
FIRST, the National Eczema Association
(NEA), the National Psoriasis Founda-
tion (NPF), International Pachyonychia
Congenita Consortium (IPCC), and
PHACE Syndrome Community. Leaders
from each group gave presentations on
the background of the disease and
history of their respective organizations.
They shared their accomplishments and
the challenges still faced by patients in
diagnosis and clinical care. Education
and translational research are among
the top priorities of all the organizations.
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Over the years, these organizations have
not only connected with patients by
providing emotional support, informa-
tion, and advocacy, but they have also
worked closely with academic centers
worldwide to prioritize research goals to
reduce morbidity and mortality and
improve patient quality of life. For over
a decade, these groups have contributed
a significant amount of grant support to
research and the training of future clin-
ician scientists.
Business meeting of PeDRA
PeDRA co-chairs, Amy Paller of North-
western University and Lawrence
Eichenfield, reviewed the history and
goals of PeDRA, highlighting the
achievements of PeDRA’s first year.
Anna Bruckner, Chair of the Member-
ship Committee, reminded attendees
that membership for this first year is
free, and encouraged participation in
an upcoming survey to provide informa-
tion for the PeDRA member database.
Fundraising Committee Chair, Moise
Levy, Dell Children’s Medical Center,
emphasized the need for unrestricted
grants and other funds from members,
industry partners, the Dermatology
Foundation and other organizations,
and philanthropists for infrastructure
costs. Without administrative support
and, in the future, funding to support
database establishment, statistical ana-
lysis, and ideally tissue banking, the role
of PeDRA in driving pediatric dermatol-
ogy research will be more limited.
Kimberly Morel, Columbia University,
Chair of the Communications Commit-
tee, noted Wynnis Tom’s success in
initiating a PeDRA website, which
will be further developed. Regular com-
munication to advocacy groups, genera-
tion of a PeDRA newsletter, and out-
reach through social media such as
Facebook are planned for the future.
Finally, Dawn Siegel, MCW, co-Chair
of the Scientific Committee, lauded the
committee’s conference preparation, a
task that required garnering an NIH
grant, program construction, and
abstract review. Moving forward, a key
role of the Scientific Committee will be
to track the progress of the disease-
specific groups to ensure focus on pro-
jects that best utilize collaboration and
engagement of a broad ensemble of
interested pediatric dermatologists and
other skin researchers.
Conclusions and next steps
This First Annual PeDRA meeting ful-
filled its mission of bringing pediatric
dermatologists, scientists, and advocacy
group partners together to network and
begin to forge a pathway toward alli-
ance goals. Participants confirmed their
strong commitment toward collabora-
tion to increase the power and capacity
for basic, clinical, and translational
research aimed at increasing therapeutic
options for pediatric skin disorders.
Patient advocacy partners reinforced an
urgent call for research directed toward
better understanding and treatment of
pediatric dermatoses. Representatives of
successful coalitions of other pediatric
specialists and university-based research
consortiums emphasized keys to success
in research organization development,
navigating institutional IRBs, and opti-
mal use of institutional resources. Meet-
ings among the four disease-focused
subgroups led to planning for collabora-
tive investigations of inflammatory skin
diseases, vascular lesions, ichthyoses
and neonatal skin care, and epidermo-
lysis bullosa and other genetic disorders,
such as basal cell carcinoma nevus
syndrome.
PeDRA has made great progress in its
first year in establishing an administrative
structure and working committees, as
well as in conducting this NIH-funded
research meeting. These accomplish-
ments will be expanded through
conference calls and at upcoming meet-
ings of the Society for Investigative Der-
matology and Society for Pediatric
Dermatology. Planning is underway for
the Second Annual PeDRA Conference
to be held in Chicago, 7–9 November
2014.
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